Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfer-factor therapy in multiple sclerosis.

P O Behan, W F Durward, I D Melville

    Lancet (London, England)
    |May 8, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Mental health in New Zealand.

    International psychiatry : bulletin of the Board of International Affairs of the Royal College of Psychiatrists·2019
    Same author

    Abstracts of the proceedings of the 20th annual meeting of the irish neurological association held on 25th-26th may, 1984.

    Irish journal of medical science·2016
    Same author

    Abnormalities of carnitine metabolism in chronic fatigue syndrome.

    European journal of neurology·2013
    Same author

    Sedimentation Rate of Stored Blood, using Sequestrene as the Anticoagulant.

    British medical journal·2010
    Same author

    Myasthenic crisis.

    QJM : monthly journal of the Association of Physicians·2008
    Same author

    Treatment of multiple sclerosis: beyond the NICE guidelines.

    QJM : monthly journal of the Association of Physicians·2005
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    Same journal

    Dual mobility total hip replacement in fractures: stability promotes patient confidence.

    Lancet (London, England)·2026
    Same journal

    Dual mobility versus standard cups in total hip replacement for displaced femoral neck fractures (Duality): an international, multicentre, randomised, controlled, superiority trial.

    Lancet (London, England)·2026
    See all related articles

    Transfer factor, derived from donors, did not alter the clinical progression of multiple sclerosis (M.S.) in patients. Both transfer factor and placebo treatments yielded similar outcomes in patient assessments and clinical examinations.

    Area of Science:

    • Immunology
    • Neurology
    • Clinical Medicine

    Background:

    • Multiple sclerosis (M.S.) is a chronic demyelinating disease of the central nervous system.
    • Immunomodulatory therapies are explored for managing M.S. progression.
    • Transfer factor is an immunologically active extract investigated for therapeutic potential.

    Purpose of the Study:

    • To evaluate the efficacy of transfer factor in modifying the clinical course of multiple sclerosis.
    • To compare the effects of transfer factor versus placebo in M.S. patients.

    Main Methods:

    • A randomized, placebo-controlled study involving 30 patients with multiple sclerosis (15 male, 15 female).
    • Patients received either transfer factor or physiological saline (placebo).
    • Clinical outcomes were assessed through independent neurological examinations and patient self-assessments.

    Related Experiment Videos

    Main Results:

    • No significant difference was observed in clinical outcomes between the transfer factor group and the placebo group.
    • Independent neurological assessments showed no differential effect.
    • Patient-reported subjective assessments also indicated no benefit from transfer factor.

    Conclusions:

    • Transfer factor administration did not demonstrate a therapeutic effect on the clinical course of multiple sclerosis in this study.
    • The findings suggest that transfer factor is not effective in treating multiple sclerosis.
    • Further research may be needed to explore other immunomodulatory agents for M.S.